Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
about
Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next StepNew Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical TrialsTargeted Therapies in Liver Fibrosis: Combining the Best Parts of Platelet-Derived Growth Factor BB and Interferon GammaNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentMolecular mechanism and treatment of viral hepatitis-related liver fibrosis.CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatmentAn algorithm that predicts the viability and the yield of human hepatocytes isolated from remnant liver pieces obtained from liver resections.Pathobiology of liver fibrosis: a translational success storyThe influence of astragalus polysaccharide and β-elemene on LX-2 cell growth, apoptosis and activation.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionMiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.The role of chemokines in hepatitis C virus-mediated liver diseaseStatus of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.Intestinal fibrosis: ready to be reversed.Hepatic stellate cells as key target in liver fibrosis.Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway.Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?Mechanisms behind the increased vulnerability of the aging stomach to NSAID-related injury: perhaps not as simple as we may think.Increased vulnerability of the aging stomach to NSAIDs.Forkhead Box F1 represses cell growth and inhibits COL1 and ARPC2 expression in lung fibroblasts in vitro.PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review).Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration.
P2860
Q26771518-5D847853-C28A-4DD7-A8D3-B45BADC584D6Q26772800-E198CA7F-FE39-489B-A751-CE29338C4370Q26779055-B9F56125-E936-4E84-90D8-1109F8083FB0Q26851211-88ECB547-787A-4399-ABEE-6E085A016FE0Q27692609-FEB05C8D-2672-438A-A7EA-31D58B0716EAQ30596736-A0D4F527-274A-4CE6-B912-DF598CC35BBFQ34250591-C865548E-65C0-4C10-9FFB-F5D3E008D940Q34337858-D153B819-13D6-4730-8DCA-54638E2C0C07Q34462733-1A7D5233-8F87-4056-8DC8-5CF09A7E1CC5Q34978907-25F829E7-ED9A-431D-84F3-5581676CF345Q35740334-DD8D6C9D-9F0B-442E-BED5-A7C944C49226Q37745389-7FF5B1F9-63EA-4FDD-A9B4-8DE162990E0CQ38197441-69947581-CE1F-484C-A9BF-09944DDA686EQ38820953-F78E6217-296C-40C1-96B4-5EB3FF86EA4BQ39237846-C333EF79-E05C-4C92-8A98-E7812E7EB527Q40200602-33FA017A-741E-4019-A663-FB52E166DC2EQ41152963-EAE47D0E-49D0-4BE1-B478-DDBCFD41C51BQ43104909-78DBEA70-D891-47DA-8A83-3E6253AD1EAFQ43194424-995133ED-752F-4714-8139-B2D8FEA90377Q45947831-B1B1BD1D-83DA-4807-806D-1FA05B07CDF2Q46312808-FBF07BCC-1EDA-473E-BAD6-64AAA044F2BBQ47741187-CD79EFAA-9FD8-4B3E-AD42-B67F7A74061DQ49568112-0EC9C307-A0DD-4600-A8EB-9AE1282D52F3Q49788208-FDB65ACF-EC25-4602-A92B-CB183755406EQ50876050-246AE9F4-6197-468A-A19E-30983713A3E3
P2860
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@en
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@nl
type
label
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@en
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@nl
prefLabel
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@en
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@nl
P2093
P2860
P1476
Antifibrotic activity of soraf ...... nd window of efficacy in vivo.
@en
P2093
Hsini Chou
Maria Isabel Fiel
Scott L Friedman
P2860
P2888
P304
P356
10.1007/S10620-012-2314-1
P577
2012-08-24T00:00:00Z